Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017
Albany, New York, Feb 08, 2017
"Global
Royalty Financing Partnering Terms and Agreements in Pharma, Biotech
and Diagnostics 2010-2017"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
The
Global Royalty Financing Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics 2010-2017 report provides comprehensive
understanding and unprecedented access to the royalty financing
agreements entered into by the worlds leading biopharma companies.
The
report provides a detailed understanding and analysis of how and why
companies enter business, royalty financing agreements.
The
focus of the report is on partnerships for royalty assets where
partners have entered an agreement to dispose of or acquire said
assets.
The report provides access to royalty financing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product
Revenue assets also known as synthetic royalties, where a specialist investment company acquires the rights to a proportion of future revenue streams in return for a lump sum payment to the company
Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred contract documents provide this insight where press releases and databases do not.
This report provides comprehensive access to royalty and revenue financing deals as announced in the life sciences industry since 2010.
This report contains links to online copies of actual royalty financing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.
The initial chapters of this report provide an orientation of royalty financing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in royalty financing dealmaking as well as a discussion on the merits and attributes of royalty financing dealmaking.
Chapter 3 provides an overview of the structure of royalty financing deal contracts. The chapter includes numerous case studies to enable understanding of royalty financing deals for royalty assets.
Chapter 4 provides a review of the leading royalty financing deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides a comprehensive listing of royalty financing contract documents since 2010, including deal value, press release and contract document.
The chapter is organized by company A-Z.
Chapter 6 provides a comprehensive listing of all royalty financing deal announcements and agreement contracts since 2010 available in the public domain. The chapter is organized by company A-Z and therapeutic area. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in royalty financing dealmaking.
In conclusion, this report provides everything a prospective dealmaker needs to know about royalty financing, enabling thorough learning, education and due diligence prior and during the royalty financing dealmaking process.
The report provides access to royalty financing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Royalty assets - where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product
Revenue assets also known as synthetic royalties, where a specialist investment company acquires the rights to a proportion of future revenue streams in return for a lump sum payment to the company
Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred contract documents provide this insight where press releases and databases do not.
This report provides comprehensive access to royalty and revenue financing deals as announced in the life sciences industry since 2010.
This report contains links to online copies of actual royalty financing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.
The initial chapters of this report provide an orientation of royalty financing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in royalty financing dealmaking as well as a discussion on the merits and attributes of royalty financing dealmaking.
Chapter 3 provides an overview of the structure of royalty financing deal contracts. The chapter includes numerous case studies to enable understanding of royalty financing deals for royalty assets.
Chapter 4 provides a review of the leading royalty financing deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides a comprehensive listing of royalty financing contract documents since 2010, including deal value, press release and contract document.
The chapter is organized by company A-Z.
Chapter 6 provides a comprehensive listing of all royalty financing deal announcements and agreement contracts since 2010 available in the public domain. The chapter is organized by company A-Z and therapeutic area. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in royalty financing dealmaking.
In conclusion, this report provides everything a prospective dealmaker needs to know about royalty financing, enabling thorough learning, education and due diligence prior and during the royalty financing dealmaking process.
** Key benefits
Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 provides the reader with the following key benefits:
In-depth understanding of royalty financing partnering deal trends since 2010
Analysis of the structure of royalty financing partnering agreements with numerous real life case studies
Comments
Post a Comment